Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jaidol-P is a fixed-dose combination analgesic and anti-inflammatory medication containing aceclofenac and paracetamol. Aceclofenac is a phenylacetic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) that works by inhibiting the cyclooxygenase (COX) enzymes, thereby reducing the synthesis of inflammatory prostaglandins. Paracetamol, also known as acetaminophen, serves as an analgesic and antipyretic agent, likely exerting its effects through the inhibition of prostaglandin synthesis in the central nervous system and modulation of the endocannabinoid system. This combination is marketed by Mandevis Pharma for the management of pain and inflammation associated with musculoskeletal disorders such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aceclofenac + paracetamol (Mandevis Pharma).